Drug intelligence / Profile preview

N-[(1S)-1-(aminocarbonyl)-4-(ethanimidoylamino)butyl]benzamide

Development stage: Preclinical
Modality: Small Molecules

Overview

This compound is a small molecule belonging to the class of hippuric acids and derivatives. It is involved in calcium ion binding and targets the protein-arginine deiminase type-4 (PADI4). The drug is experimental and has not been approved for any conditions.

Other names: N-[(1S)-1-(aminocarbonyl)-4-(ethanimidoylamino)butyl]benzamide(2S)-5-((E)-(1-aminoethylidene)amino)-2-(phenylformamido)pentanamide(2S)-5-[(E)-(1-aminoethylidene)amino]-2-(phenylformamido)pentanamide

Targets

PADI4 (Peptidyl arginine deiminase 4)

Beyond the preview

Go deeper on N-[(1S)-1-(aminocarbonyl)-4-(ethanimidoylamino)butyl]benzamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-[(1S)-1-(aminocarbonyl)-4-(ethanimidoylamino)butyl]benzamide.

Explore the full profile